deltatrials
Completed OBSERVATIONAL NCT02921035

Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

A Multicenter, Prospective, Non-interventional Study to Assess Adherence to Treatment for patIeNts With RMS Who Are Prescribed Subcutaneous (sc) Interferon Beta-1a (MAIN-MS)

Sponsor: Merck KGaA, Darmstadt, Germany

Conditions Relapsing Multiple Sclerosis (RMS)
Interventions Rebif (Interferon beta-1a)
Updated 22 times since 2017 Last updated: Mar 22, 2022 Started: Jun 30, 2016 Primary completion: Jul 27, 2020 Completion: Jul 27, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Relapsing Multiple Sclerosis (RMS), this trial is completed. The trial is conducted by Merck KGaA, Darmstadt, Germany and has accumulated 22 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Nov 2017 · 3 months · monthly snapshot~Nov 2017 – ~Feb 2018 · 3 months · monthly snapshot~Feb 2018 – ~Apr 2018 · 59 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Jan 2019 · 5 months · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Oct 2019 · 3 months · monthly snapshot~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~Sep 2020 · 6 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~May 2022 · 12 months · monthly snapshot~May 2022 – ~Jul 2024 · 26 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

22 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Sep 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. May 2022 — Jul 2024 [monthly]

    Completed

  5. May 2021 — May 2022 [monthly]

    Completed

▶ Show 17 earlier versions

  1. Jan 2021 — May 2021 [monthly]

    Completed

  2. Oct 2020 — Jan 2021 [monthly]

    Completed

    Status: Active Not Recruiting → Completed

  3. Sep 2020 — Oct 2020 [monthly]

    Active Not Recruiting

  4. Mar 2020 — Sep 2020 [monthly]

    Active Not Recruiting

  5. Oct 2019 — Mar 2020 [monthly]

    Active Not Recruiting

  6. Jul 2019 — Oct 2019 [monthly]

    Active Not Recruiting

  7. Apr 2019 — Jul 2019 [monthly]

    Active Not Recruiting

  8. Jan 2019 — Apr 2019 [monthly]

    Active Not Recruiting

  9. Aug 2018 — Jan 2019 [monthly]

    Active Not Recruiting

    Status: Recruiting → Active Not Recruiting

  10. Jul 2018 — Aug 2018 [monthly]

    Recruiting

  11. Jun 2018 — Jul 2018 [monthly]

    Recruiting

  12. Apr 2018 — Jun 2018 [monthly]

    Recruiting

    Phase: NA → None

  13. Feb 2018 — Apr 2018 [monthly]

    Recruiting NA

  14. Nov 2017 — Feb 2018 [monthly]

    Recruiting NA

  15. Aug 2017 — Nov 2017 [monthly]

    Recruiting NA

  16. Feb 2017 — Aug 2017 [monthly]

    Recruiting NA

  17. Jan 2017 — Feb 2017 [monthly]

    Recruiting NA

    First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck KGaA, Darmstadt, Germany
  • Merck Serono Middle East FZ LLC
Data source: Merck KGaA, Darmstadt, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Al Mansurah, Egypt , Alexandria, Egypt , Algiers, Algeria , Annaba, Algeria , Beirut, Lebanon , Blida, Algeria , Budapest, Hungary , Cairo, Egypt , Casablanca, Morocco , Dammam, Saudi Arabia and 25 more locations